A
Aernout Luttun
Researcher at Katholieke Universiteit Leuven
Publications - 122
Citations - 11159
Aernout Luttun is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Progenitor cell & Angiogenesis. The author has an hindex of 46, co-authored 118 publications receiving 10412 citations. Previous affiliations of Aernout Luttun include University of Minnesota & University College London.
Papers
More filters
Journal ArticleDOI
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
Peter Carmeliet,Lieve Moons,Aernout Luttun,Valeria Vincenti,Veerle Compernolle,Maria De Mol,Yan Wu,Françoise Bono,Laetitia Devy,Heike Beck,Dimitri Scholz,Till Acker,Tina DiPalma,Mieke Dewerchin,Agnès Noël,Ingeborg Stalmans,Adriano Barra,S. Blacher,Thierry VandenDriessche,Annica Pontén,Ulf Eriksson,Karl H. Plate,Jean-Michel Foidart,Wolfgang Schaper,D. Stephen Charnock-Jones,Daniel J. Hicklin,Jean-Marc Herbert,Desire Collen,M. Graziella Persico +28 more
TL;DR: It is reported that embryonic angiogenesis in mice was not affected by deficiency of PlGF, andTransplantation of wild-type bone marrow rescued the impairedAngiogenesis and collateral growth in Pgf−/− mice, indicating that PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow–derived cells.
Journal ArticleDOI
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
Aernout Luttun,Marc Tjwa,Lieve Moons,Yan Wu,Anne Angelillo-Scherrer,Francesca-Fang Liao,Janice A. Nagy,Andrea T. Hooper,Josef Priller,Bert De Klerck,Bert De Klerck,Veerle Compernolle,Evis Daci,Peter Bohlen,Mieke Dewerchin,Jean Marc Herbert,Roy A. Fava,Patrick Matthys,Patrick Matthys,Geert Carmeliet,Desire Collen,Harold F. Dvorak,Daniel J. Hicklin,Peter Carmeliet +23 more
TL;DR: PlGF stimulated angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to vascular endothelial growth factor (VEGF) and an antibody against Flt1 suppressed neovascularization in tumors and isChemic retina, and angiogenic and inflammatory joint destruction in autoimmune arthritis.
Journal ArticleDOI
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Stephane Heymans,Aernout Luttun,Dieter Nuyens,Gregor Theilmeier,Esther E. Creemers,Lieve Moons,G D Dyspersin,Jack P.M. Cleutjens,M Shipley,A Angellilo,Marcel Levi,O Nübe,Andrew Baker,Eli Keshet,Florea Lupu,Jean-Marc Herbert,Jos F.M. Smits,Steven D. Shapiro,Myriam Baes,Marcel Borgers,Desire Collen,Mat J.A.P. Daemen,Peter Carmeliet +22 more
TL;DR: Temporary administration of PA inhibitor-1 or the matrix metalloproteinase-inhibitor TIMP-1 completely protected wild-type mice against rupture but did not abort infarct healing, thus constituting a new approach to prevent cardiac rupture after acute myocardial infarction.
Journal ArticleDOI
Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
Massimiliano Mazzone,Massimiliano Mazzone,Daniela Dettori,Daniela Dettori,Daniela Dettori,Rodrigo Leite de Oliveira,Rodrigo Leite de Oliveira,Sonja Loges,Sonja Loges,Thomas Schmidt,Thomas Schmidt,Bart Jonckx,Bart Jonckx,Ya Min Tian,Anthony A. Lanahan,Patrick J. Pollard,Carmen Ruiz de Almodovar,Carmen Ruiz de Almodovar,Frederik De Smet,Frederik De Smet,Stefan Vinckier,Stefan Vinckier,Julián Aragonés,Julián Aragonés,Koen Debackere,Koen Debackere,Aernout Luttun,Sabine Wyns,Sabine Wyns,Bénédicte F. Jordan,Alberto Pisacane,Bernard Gallez,Maria Grazia Lampugnani,Elisabetta Dejana,Michael Simons,Peter J. Ratcliffe,Patrick H. Maxwell,Peter Carmeliet,Peter Carmeliet +38 more
TL;DR: In this paper, the role of endothelial PHD2 in vessel shaping by implanting tumors in mice was investigated. But, the authors did not find that PHD deficiency did not affect vessel density or lumen size.
Journal ArticleDOI
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders.
TL;DR: Preclinical studies show proof‐of‐principle that PlGF and VEGFR‐1 are promising therapeutic targets to treat angiogenesis and inflammation related disorders and whether this is also true for patients.